Drug intelligence / Profile preview

smilax glabra

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

Smilax glabra is a perennial climbing plant native to China and parts of Asia. Its rhizome (root) is widely used in traditional Chinese medicine under the name 土茯苓 (tufuling) and also known as chinaroot or sarsaparilla. The dried root is typically prepared as a decoction for oral use. It has been traditionally used to treat conditions such as dysentery, joint pain (including arthritis and rheumatism), colds, skin diseases like psoriasis, syphilis and other infections[1][3][4][5]. Pharmacologically active compounds identified in Smilax glabra include dihydro-flavonol glycosides (such as astilbin), phenylpropanoid-substituted epicatechins (smiglabrone A/B), and steroidal sapogenins like sarsasapogenin[3]. Preclinical studies suggest anti-inflammatory effects via downregulation of inflammatory cytokines such as IL-1β, TNF-α, and IL-6; immunomodulatory activity; antimicrobial properties; antipsoriatic effects through inhibition of Th17 cell differentiation; hepatoprotective actions; and possible anticancer potential[1][4]. However, robust clinical evidence for these uses remains limited.

Other names
tufulingchinarootchina-rootchina root土茯苓sarsaparilla
02

Targets

IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on smilax glabra.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on smilax glabra.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call